Attached files
| file | filename |
|---|---|
| EX-23.1 - EXHIBIT 23.1 - VERTEX PHARMACEUTICALS INC / MA | a10k_2017-exhibit231.htm |
| 10-K - 10-K - VERTEX PHARMACEUTICALS INC / MA | a201710k-main.htm |
| EX-32.1 - EXHIBIT 32.1 - VERTEX PHARMACEUTICALS INC / MA | a10k_2017-exhibit321.htm |
| EX-31.2 - EXHIBIT 31.2 - VERTEX PHARMACEUTICALS INC / MA | a10k_2017-exhibit312.htm |
| EX-31.1 - EXHIBIT 31.1 - VERTEX PHARMACEUTICALS INC / MA | a10k_2017-exhibit311.htm |
| EX-21.1 - EXHIBIT 21.1 - VERTEX PHARMACEUTICALS INC / MA | a10k_2017-exhibit211.htm |
| EX-10.46 - EXHIBIT 10.46 - VERTEX PHARMACEUTICALS INC / MA | a10k_2017-exhibit1046.htm |
| EX-10.7 - EXHIBIT 10.7 - VERTEX PHARMACEUTICALS INC / MA | a10k_2017-exhibit107.htm |
| EX-4.1 - EXHIBIT 4.1 - VERTEX PHARMACEUTICALS INC / MA | a10k2017exhibit41.htm |
Exhibit 10.47
Vertex Pharmaceuticals Annual Non-Employee Board Compensation | |||
Annual Retainer | $100,000 | ||
Committee Chair Compensation | |||
Audit & Finance Committee Chair | $30,000 annual retainer | ||
Management Development & Compensation Committee Chair | $25,000 annual retainer | ||
Corporate Governance & Nominating Committee Chair | $20,000 annual retainer | ||
Science & Technology Committee Chair | $20,000 annual retainer | ||
Committee Membership Fee (Non Chairs) | |||
Audit & Finance Committee Member | $15,000 annual retainer | ||
Management Development & Compensation Committee Member | $12,500 annual retainer | ||
Corporate Governance & Nominating Committee Member | $10,000 annual retainer | ||
Science & Technology Committee Member | $10,000 annual retainer | ||
Lead Independent Director Compensation | $40,000 annual retainer | ||
Annual Equity Grants | |||
On June 1 on each year of service, a $475,000 value-based award, comprised of restricted stock units ($275,000) and options ($200,000) • Options are fully vested upon grant • Restricted shares cliff vest on the 1 year anniversary of the grant date | |||
Each of our non-employee directors is eligible to defer the cash and restricted stock portion of his/her compensation set forth above and elect to receive deferred stock units that convert to common stock in specified circumstances. | |||